Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

FTSE at two-month peak as sterling falters

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 06:36pm CEST
FILE PHOTO: A man shelters under an umbrella as he walks past the London Stock Exchange

British shares edged higher on Friday and held to their highest level in two months as political uncertainties linked to Theresa's May's premiership pushed the pound lower, giving a boost to dollar-earning groups such as pharma stocks.

The FTSE 100 index <.FTSE> closed 0.2 percent up at 7,522.87 points, with Britain's pound on track for its worst week in a year as the Prime Minister hit back at a plot to topple her, saying she would provide "calm leadership" to the country.

"The talk of a leadership plot against the Prime Minister is eroding the pound's value and propping up the FTSE 100," CMC Markets analyst David Madden wrote in a note to clients.

Last month sterling strength helped the FTSE 100 to post a slight decline for September, but the currency has since been losing steam and the index has posted its biggest one-week gain since December last year.

Health stocks, which source a sizeable chunk of their revenue from the United States, were among the biggest gainers. Heavyweights GlaxoSmithKline (>> GlaxoSmithKline) and AstraZeneca (>> AstraZeneca) rose by about 0.3 percent and 1 percent respectively.

British American Tobacco (>> British American Tobacco) was up 1.6 percent and Imperial Brands (>> Imperial Brands) advanced by 0.2 percent.

Shares in budget airline easyJet (>> EasyJet) dropped by 1.6 percent, the biggest FTSE 100 faller, after a price target cut from broker Credit Suisse.

The airline also posted a mixed pre-close update, with analysts pointing to pricing pressures despite easyJet reporting a record summer and saying that it expects to reach the higher end of its profit range.

"Revenue trends are improving, but pricing remains under pressure," Liberum analysts said in a note.

Credit Suisse analysts saw some supportive factors, however.

"With Monarch's failure, Air Berlin's break-up, Alitalia's administration and Ryanair capacity cuts, we expect this confluence of positives must help EZJ (easyJet) pricing," they said in a note.

Shares in building materials company CRH (>> CRH PLC) fell by 1.3 percent after its offer for U.S. Ash Grove Cement Co (>> Ash Grove Cement Co) was surpassed.

(Reporting by Kit Rees and Julien Ponthus; Editing by Keith Weir and David Goodman)

By Kit Rees and Julien Ponthus

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
10/23DJEuropean Corporate Roundup for Monday
10/23 ASTRAZENECA : among backers as Swiss cancer biotech raises $200 million
10/23 ASTRAZENECA : US FDA Approves New Easy-to-Use, Once-Weekly BYDUREON® BCise&trade..
10/23DJEuropean Corporate Roundup for Monday
10/23 ASTRAZENECA : announces new data showing US preterm infants at significantly gre..
10/23DJASTRAZENECA : New Diabetes Drug Formulation Gets FDA Approval
10/23 ASTRAZENECA : AZ and MSD rapidly advance Lynparza in Japan
10/23 ASTRAZENECA : US FDA approves new easy-to-use, once-weekly Bydureon BCise inject..
10/23 ASTRAZENECA : and MSD rapidly advance Lynparza in Japan with a second regulatory..
10/23 ASTRAZENECA : US FDA approves Bydureon BCise for type-2 diabetes
More news
News from SeekingAlpha
10/23 BIG BIOTECH IN THE CRISPR GAME : Novartis And Vertex Lead The Pack
10/23 FDA OKs new formulation of AstraZeneca's diabetes med Bydureon
10/22 WEEK IN REVIEW : WuXi AppTec Acquires U.S.-Global Clinical CRO
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 19, 2017
Financials ($)
Sales 2017 21 638 M
EBIT 2017 5 959 M
Net income 2017 2 524 M
Debt 2017 12 193 M
Yield 2017 4,00%
P/E ratio 2017 30,76
P/E ratio 2018 25,99
EV / Sales 2017 4,55x
EV / Sales 2018 4,50x
Capitalization 86 178 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 66,4 $
Spread / Average Target -2,4%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA16.33%85 977
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116